Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

Janet Napolitano net worth and biography

Janet Napolitano Biography and Net Worth

Director of Vir Biotechnology

Ms. Janet Napolitano has served on our Board since August 2020. Ms. Napolitano served as President of the University of California from September 2013 until her departure in August 2020. Prior to her time serving as the President of the University of California, she served as the U.S. Secretary of Homeland Security from 2009 to 2013, as governor of the state of Arizona from 2003 to 2009, as attorney general of Arizona from 1998 to 2003 and as U.S. attorney for the District of Arizona from 1993 to 1997. In 2010, Ms. Napolitano was awarded the University of Virginia’s Thomas Jefferson Foundation Medal for law. In 2014, Ms. Napolitano was appointed as a tenured faculty member of the University of California Berkeley’s Goldman School of Public Policy. In 2015, Ms. Napolitano was elected to the American Academy of Arts and Sciences, and in 2017, she was inducted into the American Philosophical Association. Ms. Napolitano currently serves on the Council of the American Law Institute and is a board member of Zoom Video Communications, Inc. and the Council on Foreign Relations. Ms. Napolitano holds a B.S. in political science (summa cum laude) from Santa Clara University where she was a Truman Scholar and the university’s first female valedictorian and a J.D. from the University of Virginia School of Law.

What is Janet Napolitano's net worth?: The estimated net worth of Janet Napolitano is at least $38,231.55 as of August 30th, 2021. Ms. Napolitano owns 4,809 shares of Vir Biotechnology stock worth more than $38,232 as of April 19th. This net worth estimate does not reflect any other investments that Ms. Napolitano may own. Learn More about Janet Napolitano's net worth.
How do I contact Janet Napolitano?: The corporate mailing address for Ms. Napolitano and other Vir Biotechnology executives is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. Vir Biotechnology can also be reached via phone at 415-906-4324 and via email at [email protected]. Learn More on Janet Napolitano's contact information.
Has Janet Napolitano been buying or selling shares of Vir Biotechnology?: Janet Napolitano has not been actively trading shares of Vir Biotechnology in the last ninety days. Most recently, Janet Napolitano sold 1,435 shares of the business's stock in a transaction on Tuesday, November 30th. The shares were sold at an average price of $46.25, for a transaction totalling $66,368.75. Learn More on Janet Napolitano's trading history.
Who are Vir Biotechnology's active insiders?: Vir Biotechnology's insider roster includes Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?: In the last twelve months, insiders at the sold shares 29 times. They sold a total of 1,223,402 shares worth more than $29,197,063.35. The most recent insider tranaction occured on April, 3rd when CEO Backer Marianne De sold 72,995 shares worth more than $690,532.70. Insiders at Vir Biotechnology own 18.1% of the company. Learn More about insider trades at Vir Biotechnology.
Information on this page was last updated on 4/3/2024.

Janet Napolitano Insider Trading History at Vir Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/30/2021	Sell	1,435	$46.25	$66,368.75
8/30/2021	Sell	1,435	$51.15	$73,400.25	4,809

Janet Napolitano Buying and Selling Activity at Vir Biotechnology

Vir Biotechnology Company Overview

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Today's Range

Now: $7.95

$7.76

$8.21

50 Day Range

MA: $10.12

$7.95

$11.90

2 Week Range

Now: $7.95

$7.72

$27.48

Volume

1,072,364 shs

Average Volume

1,046,171 shs

Market Capitalization

$1.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.41

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad